We are excited to announce Vickino’s appointment as a strategic advisor to Caraxel AI to transform pharmacovigilance. Co-founded by Artur Gasparyan and Vitali Avagyan, Caraxel AI leads the charge in revolutionizing pharmacovigilance through AI-powered healthcare solutions.
The AI-driven Pharmacovigilance Co-Pilot streamlines the monitoring, retrieval, and evaluation of scientific literature in multiple languages. This innovation accelerates real-time identification of adverse events and emerging risks, facilitating quicker decision-making.
By integrating advanced AI, Caraxel AI significantly cuts the time and resources spent on traditional pharmacovigilance, empowering professionals to prioritize critical tasks. This enhances patient safety and ensures compliance with complex regulations.
Why This Collaboration Matters in Pharmacovigilance
Vickino’s strategic advisory role will help Caraxel AI broaden its impact. Leveraging Vickino’s expertise in digital health and technological innovation, this partnership advances Caraxel AI’s solutions, reshaping global pharmacovigilance practices and aligning with our priorities in healthcare AI for 2025.
A Shared Vision for Advancing AI Pharmacovigilance
Both Vickino and Caraxel AI are committed to improving patient safety and operational efficiency in the pharmaceutical sector. The AI-powered Pharmacovigilance Co-Pilot demonstrates AI’s ability to solve complex healthcare challenges. Together, we will drive progress in pharmacovigilance and enhance drug safety monitoring worldwide.
Stay tuned for updates on our collaboration relying on developing AI to transform pharmacovigilance. For more information about Vickino’s initiatives supporting health startups or to learn about Caraxel AI, contact us directly.
